BrainStorm Cell Therapeutics announced that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3933 USD | -2.67% |
|
+12.05% | +44.07% |
07-11 | Maxim Upgrades Brainstorm Cell Therapeutics to Buy From Hold, Price Target is $2 | MT |
07-08 | Transcript : Brainstorm Cell Therapeutics Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.07% | 31.3M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.81% | 41.55B | |
+25.40% | 30.36B | |
-4.47% | 28.7B | |
+17.96% | 27.61B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- BCLI Stock
- News Brainstorm Cell Therapeutics Inc.
- BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing